Categories
BLOG

potency of will

Potency of Will cluster – HoA virulence stacks

I just wonder, the potency of will cluster gives 45% increased skill effect duration. Does that also apply to the HoA virulence stacks, meaning that they last longer?

I just wonder, the potency of will cluster gives 45% increased skill effect duration. Does that also apply to the HoA virulence stacks, meaning that they last longer?

No, virulence stacks is not a skill, hence it cannot be affected by skill effect duration modifiers, like Increased Duration Support or normal Nodes from the tree.

Currently, the only way to make them last longer, is through Pathfinder’s Master Toxicist ascendancy node, wich makes you loose them 50% slower.

Path of Exile is a free online-only action RPG under development by Grinding Gear Games in New Zealand.

Using a mass balance to determine the potency loss during the production of a pharmaceutical blend

Affiliation

  • 1 Global Formulation Sciences-Solids, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Dept. R4P7, Bldg AP31-4, Abbott Park, Illinois 60064, USA. [email protected]
  • PMID: 20556674
  • PMCID: PMC2974127
  • DOI: 10.1208/s12249-010-9466-0

Free PMC article

Using a mass balance to determine the potency loss during the production of a pharmaceutical blend

  • Search in PubMed
  • Search in NLM Catalog
  • Add to Search

Author

Affiliation

  • 1 Global Formulation Sciences-Solids, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Dept. R4P7, Bldg AP31-4, Abbott Park, Illinois 60064, USA. [email protected]
  • PMID: 20556674
  • PMCID: PMC2974127
  • DOI: 10.1208/s12249-010-9466-0

Abstract

The manufacture of a blend containing the active pharmaceutical ingredient (API) and inert excipients is a precursor for the production of most pharmaceutical capsules and tablets. However, if there is a net water gain or preferential loss of API during production, the potency of the final drug product may be less than the target value. We use a mass balance to predict the mean potency loss during the production of a blend via wet granulation and fluidized bed drying. The result is an explicit analytical equation for the change in blend potency a function of net water gain, solids losses (both regular and high-potency), and the fraction of excipients added extragranularly. This model predicts that each 1% gain in moisture content (as determined by a loss on drying test) will decrease the API concentration of the final blend at least 1% LC. The effect of pre-blend solid losses increases with their degree of superpotency. This work supports Quality by Design by providing a rational method to set the process design space to minimize blend potency losses. When an overage is necessary, the model can help justify it by providing a quantitative, first-principles understanding of the sources of potency loss. The analysis is applicable to other manufacturing processes where the primary sources of potency loss are net water gain and/or mass losses.

Figures

Total mass balance for production…

Total mass balance for production of milled granules by wet granulation, deagglomeration, drying,…

Reduction in final blend potency,…

Reduction in final blend potency, Δ P B ; f x Extra =…

Reduction in final blend potency,…

Reduction in final blend potency, Δ P B ; f , for x…

Reduction in final blend potency,…

Reduction in final blend potency, Δ P B ; f , for x…

Reduction in final blend potency,…

Reduction in final blend potency, Δ P B ; f , for x…

Reduction in final blend potency,…

Reduction in final blend potency, Δ P B ; f , for x…

Reduction in final blend potency,…

Reduction in final blend potency, Δ P B ; f , for x…

The manufacture of a blend containing the active pharmaceutical ingredient (API) and inert excipients is a precursor for the production of most pharmaceutical capsules and tablets. However, if there is a net water gain or preferential loss of API during production, the potency of the final drug prod …